10 April 2006
Comment to: Septic shock; current pathogenetic concepts from a clinical perspective.
Konstantinos G. TsalisMed Sci Monit 2006; 12(4): LE4-4 :: ID: 448942
Abstract
Dear Editor, I really enjoyed the article of Dr A. Tsiotou et al. entitled"Septic shock; current pathogenetic concepts from a clinical perspective" [1]. I found it very interestingbecause it is well known that the yearly incidence of sepsis is 50-95 cases per 100.000, and has beenincreasing by 9% each year [2]. Furthermore, 3% of patients with severe sepsis experience septic shockwhich accounts for 10% of admissions to intensive care units [3,4]. The pathophysiologic process of septicshock is an extremely complex cascade of events that includes proinflammatory, anti-inflammatory, humoral,cellular, and circulatory involvement [5]. These factors are extensively and analytically reviewed inthis article. Excessive production of Nitric Oxide(NO) has been implicated in the pathogenesis of septicshock for a long time. As it is noticed in the article, the inhibition of NO in the context of septicshock in experimental models has demonstrated a survival advantage. But it has to be noticed that inthe pivotal clinical trial for the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride(546C88)the mortality was higher in the treatment arm [6]. Furthermore, another clinical trial showed that theintravenous administration of the nitric oxide synthase inhibitor 546C88 had as a result more rapid shockresolution although with reduced cardiac output and no survival difference [7,8]. Critical illness polyneuropathyand polymyopathy is a syndrome that has to be always mentioned when facing patients with sepsis because,as it is noticed in this review, the incidence is often more than 50% in ICU patients. Finally it iswell pointed out in this review that sometimes organ dysfunction may be due to a therapeutic intervention.The use of packed erythrocyte transfusions, for example, is associated with the transmission of potentialviral and bacterial infections, immune modulation, graft-versus-host disease, volume overload, and transfusion-relatedacute lung injury [9,10]. Administration of packed erythrocytes has also been suspected of triggeringa proinflammatory response that may serve as a "second hit" which could trigger the development of multipleorgan dysfunction syndrome [11]. Thus the patient with sepsis is subject to the various complicationsthat are frequently encountered in the critically ill patient, many of which are preventable with theuse of prophylactic strategies. Sincerelly, Konstantinos G. Tsalis, Associate Professor of Surgery, SurgicalDepartment, Aristotle University of Thessaloniki, Thessaloniki, Greece, e-mail: [email protected] References:1. Tsiotou AG, Sakorafas GH, Anagnostopoulos G, Bramis J: Septic shock; current pathogenetic conceptsfrom a clinical perspective. Med Sci Monit, 2005; 11(3): RA76-85 2. American College of Chest Physicians/Societyof Critical Care Medicine. Consensus Conference: definitions for sepsis and organ failure and guidelinesfor the use of innovative therapies in sepsis. Crit Care Med, 1992; 20: 864-74 3. Rangel-Frausto MS,Pittet D, Hwang T et al: The dynamics of disease progression in sepsis: Markov modeling describing thenatural history and the likely impact of effective antisepsis agents. Clin Infec Dis, 1998; 27: 185-904. Annane D, Aegerter P, Jars-Guinsestre MC, Guidet B: Current epidemiology of septic shock: the CUB-ReaNetwork. Am J Respir Crit Care Med, 2003; 1687: 165-72 5. Hotchkiss RS, Karl IE: The pathophysiologyand treatment of sepsis. N Engl J Med, 2003; 342: 138-50 6. Lopez A, Lorente JA, Steingrub J et al: Multiple-center,randomized, placebo-controlled, double-blind study of nitric oxide synthase inhibitor 546C88: effecton survival in patients with septic shock. Crit Care Med, 2004; 32: 21-30 7. Watson D, Grover R, AnzuetoA, et al. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride(546C88)in patients with septic shock: results of a randomised, double-blind, placebo-controlled multicenterstudy(study no. 144-002). Crit Care Med, 2004; 32: 13-20 8. Bakker J, Griver R, McLuckie A et al: Administrationof nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride(546C88) by intravenous infusionfor up to 72 hours can promote the resolution of shock in patients with severe sepsis; results of a randomised,double-blind, placebo-controlled multicenter study(study no.144-002). Crit Care Med, 2004; 32-1-12 9.Kopko PM, Marshall CS, Mackenzie MR: Transfusion-related acute lung injury. JAMA, 2002; 287: 1968-7110. Tsalis K, Ganidou M, Blouchos K et al: Transfusion related acute lung injury: a life threateningtransfusion reaction. Med Sci Monit, 2005; 11(5): CS19-22 11. Aiboshi J, Moore EE, Ciesla DJ et al: Bloodtransfusion and the two-insult model of post-injury multiple organ failure. Shock, 2001; 12: 302-6.
Keywords: Nitric Oxide - metabolism, Shock, Septic - pathology
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952